Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma
The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Ma...
Source: BMC Pulmonary Medicine - Category: Respiratory Medicine Authors: Steven G. Gray Tags: Review Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Immunotherapy | Lung Cancer | Mesothelioma | Non-Small Cell Lung Cancer | Respiratory Medicine